Balancing Innovation And Flexibility In Early Cell Therapy Manufacturing Technologies

In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman explains that introducing advanced analytics, automation, and digital tools early can strengthen process control and sterility, but startups must weigh innovation against practical constraints. Luke emphasizes the importance of building systems that are ready for advanced analytics even if they’re not yet implemented, suggesting thoughtful sample planning and retention to enable future insights.